Agreements

* On September 27, 2013,  Sanofi and Aviesan, the French National Alliance for Life Sciences and Health have announced that they have renewed for a period of three years the cooperation protocol signed in 2010. The aim is to contribute to the development of new treatments that target unmet medical needs, including those in the field of rare diseases, to participate to the excellence and consolidation of research in French industry on an international level. Special emphasis will be put on translational research projects that bring together clinical and medical teams with fundamental research teams to translate research successes into medical advances.

Several projects under this new protocol are under discussion, including the creation of centers of excellence as part of future investments, particularly in collaboration with IHUs (University Hospital Institutes) and IRTs (Technological Research Institutes).

The new cooperation between Aviesan and Sanofi research teams will also spur the development of technology platforms to finance the work of researchers (e.g. the ATIP-Avenirs program), CIFRE fellows, post-docs, and staff secondment. A Strategy Committee and an Operational Steering Committee, each consisting of eight directors divided equally between Aviesan and Sanofi, will coordinate interactions between the different players, as well as preparing and validating projects and monitoring their implementation.

The cooperation protocol signed in 2010 between Sanofi and Aviesan is based on three pillars. First, collaboration agreements with Aviesan research teams. Second, the creation of teams of young researchers supported by additional funding from the ATIP-Avenirs program, a joint CNRS and INSERM initiative. Third, Sanofi is a member of the COPIO (interagency SteeringCommittee) tasked with setting up and bringing to maturity inter-agency projects that help with medical progress and the development of the healthcare industry, through which Sanofi has funded several projects.In three years, Sanofi has signed 15 collaborative projects with Aviesan’s French teams of academic excellence, as well as providing additional funding to 16 young scientists who won ATIP-Avenirs grants and investing in four COPIO projects. Over 10 million euros were invested by Sanofi in 2012 for these collaborations.